Difference between revisions of "Bicalutamide (Casodex)"
Jump to navigation
Jump to search
| Line 17: | Line 17: | ||
*10/4/1995: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]. ''(Based on Schellhammer et al. 1995)'' | *10/4/1995: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]. ''(Based on Schellhammer et al. 1995)'' | ||
**12/12/1997: Converted to regular approval. | **12/12/1997: Converted to regular approval. | ||
| − | |||
==Also known as== | ==Also known as== | ||
Revision as of 18:02, 23 August 2022
General information
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bicalutamide (Casodex) package insert[1]
- Bicalutamide (Casodex) patient drug information (Chemocare)[3]
- Bicalutamide (Casodex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 10/4/1995: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
- 12/12/1997: Converted to regular approval.
Also known as
- Brand names: Casodex, Cosudex, Calutide, Kalumid